Tesamorelin Information

Tesamorelin is a synthetic growth hormone-releasing factor (GHRF) analog.

Its primary medical use is to reduce the amount of excess abdominal fat (visceral adipose tissue) in adults with Human Immunodeficiency Virus (HIV) who have developed lipodystrophy. Lipodystrophy is a condition characterized by abnormal fat redistribution and metabolic changes often associated with antiretroviral therapy for HIV.

How Tesamorelin Works:

Tesamorelin works by mimicking the function of the body's natural Growth Hormone-Releasing Hormone (GHRH), which is produced in the hypothalamus of the brain.

1. Stimulates the Pituitary Gland: Tesamorelin binds to GHRH receptors in the anterior pituitary gland.
2. Increases Growth Hormone (GH) Secretion: This binding stimulates the pituitary gland to increase the production and release of endogenous growth hormone (GH).
3. Increases IGF-1: The released GH then acts on various tissues, including the liver, where it stimulates the production of Insulin-like Growth Factor-1 (IGF-1). IGF-1 mediates many of the effects of growth hormone.
4. Promotes Lipolysis: The increased levels of GH and IGF-1 are thought to lead to a combination of anabolic (muscle-building) and lipolytic (fat-breakdown) effects. The main mechanism by which Tesamorelin reduces excess abdominal fat is through lipolysis (the breakdown of fats and other lipids). This effect is specifically targeted at visceral adipose tissue (fat deep inside the abdomen, surrounding the organs) rather than subcutaneous fat (fat just under the skin).

In summary, Tesamorelin acts upstream of growth hormone, increasing its natural pulsatile secretion, which in turn leads to the breakdown and reduction of the excess visceral fat associated with HIV-lipodystrophy.